These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 418268)

  • 21. Normalization of retinal vascular permeability in experimental diabetes with genistein.
    Nakajima M; Cooney MJ; Tu AH; Chang KY; Cao J; Ando A; An GJ; Melia M; de Juan E
    Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2110-4. PubMed ID: 11481279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats.
    Agardh E; Hultberg B; Agardh C
    Curr Eye Res; 2000 Jul; 21(1):543-9. PubMed ID: 11035534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Water extract of Aralia elata prevents cataractogenesis in vitro and in vivo.
    Chung YS; Choi YH; Lee SJ; Choi SA; Lee JH; Kim H; Hong EK
    J Ethnopharmacol; 2005 Oct; 101(1-3):49-54. PubMed ID: 15905053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Refractive change in alloxan diabetic rabbits. Control by flavonoids I.
    Varma SD; El-Aguizy HK; Richards RD
    Acta Ophthalmol (Copenh); 1980 Oct; 58(5):748-59. PubMed ID: 6782822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of aldose reductase inhibitor on retinal microangiopathy in streptozotocin-diabetic rats.
    Kojima K; Matsubara H; Harada T; Mizuno K; Suzuki M; Hotta N; Kakuta H; Sakamoto N
    Jpn J Ophthalmol; 1985; 29(1):99-109. PubMed ID: 3159927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cataract formation is prevented by administration of verapamil to diabetic rats.
    Pierce GN; Afzal N; Kroeger EA; Lockwood MK; Kutryk MJ; Eckhert CD; Dhalla NS
    Endocrinology; 1989 Aug; 125(2):730-5. PubMed ID: 2752974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats.
    Rota R; Chiavaroli C; Garay RP; Hannaert P
    Eur J Pharmacol; 2004 Jul; 495(2-3):217-24. PubMed ID: 15249173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Etiology of cataracts in diabetics.
    Varma SD; Richards RD
    Int Ophthalmol Clin; 1984; 24(4):93-110. PubMed ID: 6438012
    [No Abstract]   [Full Text] [Related]  

  • 30. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
    El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
    Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory activities of prenylated flavonoids from Sophora flavescens against aldose reductase and generation of advanced glycation endproducts.
    Jung HA; Yoon NY; Kang SS; Kim YS; Choi JS
    J Pharm Pharmacol; 2008 Sep; 60(9):1227-36. PubMed ID: 18718128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Quantitative study of rat diabetic cataract, by the relaxation times of nuclear magnetic resonance].
    Mori K; Terubayashi H; Akagi Y; Okamoto S; Tsutsumi M; Ikebe H; Yoshizaki K; Nishikawa H
    Nippon Ganka Gakkai Zasshi; 1991 Apr; 95(4):336-42. PubMed ID: 1908617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldose reductase inhibition and retinopathy.
    Robison WG
    Diabetes; 1994 Feb; 43(2):337-9. PubMed ID: 8288059
    [No Abstract]   [Full Text] [Related]  

  • 34. Flavonoids as inhibitors of lens aldose reductase.
    Varma SD; Mikuni I; Kinoshita JH
    Science; 1975 Jun; 188(4194):1215-6. PubMed ID: 1145193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches.
    Costantino L; Rastelli G; Vianello P; Cignarella G; Barlocco D
    Med Res Rev; 1999 Jan; 19(1):3-23. PubMed ID: 9918192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo assessment of an animal model of diabetic cataract: medical intervention studies.
    Joon TL; Foo K; Panagiotopoulos S; Jerums G; Taylor HR
    Dev Ophthalmol; 1994; 26():57-62. PubMed ID: 7895883
    [No Abstract]   [Full Text] [Related]  

  • 37. Can cataract be prevented?
    Harding JJ
    Eye (Lond); 1999 Jun; 13 ( Pt 3b)():454-6. PubMed ID: 10627824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of venous drugs on venous capacity and capillary filtration in lower extremities in patients with chronic venous insufficiency (author's transl)].
    Roztocil K; Prerovský I; Oliva I; Hálová J
    Cas Lek Cesk; 1977 Apr; 116(14):429-31. PubMed ID: 120759
    [No Abstract]   [Full Text] [Related]  

  • 39. [Diabetic retinopathy and thrombosis: an experimental study (author's transl)].
    Ishibashi T; Tanaka K; Taniguchi Y
    Nippon Ganka Gakkai Zasshi; 1980 Aug; 84(8):878-89. PubMed ID: 7211602
    [No Abstract]   [Full Text] [Related]  

  • 40. Diabetic retinopathy: a physician's view.
    Ward JD
    Eye (Lond); 1990; 4 ( Pt 1)():169-73. PubMed ID: 2108880
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.